Literature DB >> 1674680

Should dopamine agonist treatment for prolactinomas be life-long?

G Faglia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1674680     DOI： 10.1111/j.1365-2265.1991.tb00288.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  5 in total

1.  15-year-old boy with ocular palsy and headache. Invasive macroprolactinoma.

Authors:  G Minniti; M L Jaffrain-Rea; P Lunardi; A Gulino; G Tamburrano
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

2.  Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.

Authors:  E Sala; P Bellaviti Buttoni; E Malchiodi; E Verrua; G Carosi; E Profka; G Rodari; M Filopanti; E Ferrante; A Spada; G Mantovani
Journal:  J Endocrinol Invest       Date:  2016-05-31       Impact factor: 4.256

3.  Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.

Authors:  M Muratori; M Arosio; G Gambino; C Romano; O Biella; G Faglia
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

Review 4.  Pituitary tumors. Current concepts in diagnosis and management.

Authors:  D C Aron; J B Tyrrell; C B Wilson
Journal:  West J Med       Date:  1995-04

5.  Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.

Authors:  Berçem Ayçiçek Doğan; Ayşe Arduç; Mazhar Müslüm Tuna; Narin Imga Nasıroğlu; Serhat Işık; Dilek Berker; Serdar Güler
Journal:  Anatol J Cardiol       Date:  2015-07-29       Impact factor: 1.596
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.